Browse > Article

The outcome of perinatal prophylaxis for HBeAg positive mothers according to the maternal HBV-DNA levels at the delivery time  

Jeong, On (Department of Pediatrics, College of Medicine, The Catholic University of Korea)
Kim, Jong-Hyun (Department of Pediatrics, College of Medicine, The Catholic University of Korea)
Publication Information
Clinical and Experimental Pediatrics / v.50, no.4, 2007 , pp. 348-354 More about this Journal
Abstract
Purpose : Perinatal hepatitis B viral infection is decreasing; however, 10% of babies to HBeAg positive mothers still become chronic carriers despite perinatal prophylaxis. Although, the cause of prophylaxis failure is still unclear, an importance of maternal HBV-DNA level at the delivery time has been suggested. This study was established to certify if it would be a useful predictable factor for the outcome of perinatal prophylaxis. Methods : Twenty-nine HBeAg positive mothers whose babies had known outcomes of prophylaxis were selected. To determine the amount of maternal HBV-DNA, a quantitative PCR was performed with the WHO International Standard for HBV DNA NAT assays. Results : The mean logarithm HBV-DNA level of mothers with failed outcomes was significantly higher than that of mothers with succeessful outcomes (7.99 vs. 6.72, P=0.015). The predictable maternal HBV-DNA cut-off level to prophylaxis outcome was $2.83{\times}10^7copies/mL$ (100 pg/mL). None out of the case 16 (0%) who had below this level, and 5 out of 13 (38.5%) who had above this level of maternal HBV-DNA failed in perinatal prophylaxis. Conclusion : Mothers with higher levels of HBV-DNA at delivery time would be prone to a worse outcome of prophylaxis using the conventional approach. Perinatal prophylaxis failure rate can be reduced, if we try to introduce more potent prophylactic treatment into the cases with this risk factor.
Keywords
Hepatitis B; Perinatal infection; Real time PCR; Maternal HBV-DNA; Prophylaxis failure;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 del Canho R, Grosheide PM, Mazel JA, Heijtink RA, Hop WCJ, Gerards LJ, et al. Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: protective efficacy and long-term immunogenicity. Vaccine 1997; 15:1624-30
2 Wang Z, Zhang J, Yang H, Li X, Wen S, Guo Y, et al. Quantitative analysis of HBV DNA level and HBeAg titer in hepatitis B surface antigen positive mothers and their babies: HBeAg passage through the placenta and the rate of decay in babies. J Med Virol 2003;71:360-6   DOI   ScienceOn
3 van Zonneveld M, van Nunen AB, Niesters HGM, de Man RA, Schalm SW, Janssen HLA. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 2003;10:294-7   DOI   ScienceOn
4 Hwang SH, Kim JH, Kang JH, Hur JK, Lee KY, Lee SH, et al. Follow-up of children with chronic hepatitis B virus infection. Korean J Pediatr Infect Dis 2004;11:73-80   DOI
5 Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Eng J Med 1975;292:771-4   DOI   ScienceOn
6 Marion SA, Pastore MT, Pi DW, Mathias RG. Long-term follow-up of hepatitis B vaccine in infants of carrier mothers. Am J Epidemiol 1994;140:734-46   DOI
7 Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994;331:1173-80   DOI   ScienceOn
8 Lin HH, Chang MH, Chen DS, Sung JL, Hong KH, Young YC, et al. Early predictor of the efficacy of immunoprophylaxis against perinatal hepatitis B transmission: analysisof prophylaxis failure. Vaccine 1991;9:457-60   DOI   ScienceOn
9 Soderstrom A, Norkrans G, Lindh M. Hepatitis B virus DNA during pregnancy and postpartum: aspects on vertical transmission. Scand J Infect Dis 2003;35:814-9   DOI
10 Kim JH, Kang JH, Oh CK. Immune responses and efficacy of hepatitis B vaccine in neonates born from hepatitis B carrier mothers: focus on HBV-DNA. J Korean Pediatr Soc 1998:41:1498-508
11 Kim JH, Pyo CW, Koh DK, Hur JK, Kang JH, Kim TG. Alteration of the influences of HLA classes I and II alleles on the perinatal hepatitis B virus infection after immunoprophylaxis in Korean children. Hepatol Res 2006;35:118-26   DOI   ScienceOn
12 Carman WF. The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat 1997;4 Suppl 1:11-20   DOI   ScienceOn
13 The Office for Health and Medical Care Policy in The Ministry of Health & Welfare, Division of Chronic Disease Surveillance in Korea Centers for Disease Control and Prevention. 2005 National Health and Nutrition Survey in Korea: Medical Examination Survey. Kwacheon: The Ministry of Health & Welfare, 2006:204
14 Milich DR, Jones JE, Hughes JL, Price J, Raney AK, Mclachlan A. Is a function of the secreted hepatitis B eantigen to induce immunologic tolerance in utero? Proc Natl Acad Sci USA 1990;87:6599-603
15 Kapke GF, Watson S, Sheffler S, Hunt D, Frederick C. Comparison of the Chiron Quantiplex branched DNA (bDNA) assay and the Abbott Genostics solution hybridization assay for quantification of hepatitis B viral DNA. J Viral Hepat 1997;4:67-75   DOI   ScienceOn
16 Kim JH, Koh DK, Hur JK, Kang JH, Nainan OV, Margolis HS. The incidence rate of hepatitis B virus surface gene variants in Korean children with immunoprophylaxis failure of perinatal infection. Korean J Hepatol 2005;11:320-8
17 McMahon BJ, Alward WL, Hall DB, Heyward WL, Bender TR, Francis DP, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of carrier state. J Infect Dis 1985; 151:599-603   DOI   ScienceOn
18 Kim JH, Pyo CW, Hur SS, Kim YK, Kim TG. Influences of IL-1B, IL-1RN, TNFA, and TNFB alleles on chronic HBV infection and perinatal infections of hepatitis B virus after immunoprophylaxis. Human Immunol 2003;64 Suppl 10:143
19 Ngui SL, Andrews NJ, Underhill GS, Heptonstall J, Teo CG. Failed postnatal immunoprophylaxis for hepatitis B: characteristics of maternal hepatitis B virus as a risk. Clin Infect Dis 1998;27:100-6   DOI   ScienceOn
20 Moradpour D, Wands JR. Understanding hepatitis B infection. N Engl J Med 1995;332:1092-3   DOI   ScienceOn
21 Oon CJ, Lim GK, Ye Z, Goh KT, Tan KL, Yo SL, et al. Molecular epidemiology of hepatitis B virus vaccine variants in Singapore. Vaccine 1995;13:699-702   DOI   ScienceOn
22 Wheeley SM, Jackson PT, Boxall EH, Tarlow MJ, Gatrad AR, Anderson J, et al. Prevention of perinatal transmission of hepatitis B virus(HBV): a comparison of two prophylactic schedules. J Med Virol 2001;35:212-5   DOI   ScienceOn
23 Zhang SL, Han XB, Yue YF. Relationship between HBV viremia level of pregnant women and intrauterine infection: nested PCR for detection of HBV DNA. World J Gastroenterol 1998;4:61-4
24 Andre FE, Zuckerman AJ. Review: protective efficacy of hepatitis B vaccines in neonates. J Med Virol 1994;44:144- 51   DOI   ScienceOn
25 Nainan OV, Khristova ML, Byun K, Xia G, Taylor PE, Stevens CE, et al. Genetic variation of hepatitis B surface antigen coding region among infants with chronic hepatitis B virus infection. J Med Virol 2002;68:319-27   DOI   ScienceOn
26 Kim JH, Seo K, Kim HM. A comparative study for the outcome of perinatal hepatitis B prophylaxis according to the dosages of hepatitis B immunoglobulin. Seoul : Korea Centers for Disease Control and Prevention, 2006
27 Hsu HY, Chang MH, Liaw SH, Ni YH, Chen HL. Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan. Hepatology 1999;30:1312-7   DOI
28 Nainan OV, Khristova ML, Byun KS, Xia GL, Taylor PE, Stevens CE, et al. Frequency and significance of hepatitis B virus antibody resistant mutants. Antiviral Ther 2000;5 Suppl 1:30
29 Rendi-Wagner P, Shouval D, Genton B, Lurie Y, Rumke H, Boland G, et al. Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. Vaccine 2006;24:2781-9   DOI   ScienceOn
30 Ip HMH, Lelie PN, Wong VCW, Kuhns MC, Reesink HW. Prevention of hepatitis B virus carrier state in infants according to maternal serum levels of HBV DNA. Lancet 1989;i:406-9
31 Chang JY, Cheong SJ, Kim SK, Son BK, Hong YJ, Hong KS. Positive rate of HBsAg in school children in Incheon area. Korean J Pediatr Infect Dis 2003;10:153-8   DOI
32 Choung JM, Kim JC, Eun SH, Hwang PH, Nyhambat B, Kilgore P, et al. Study on vaccination state in children: Jeonbuk Province, 2000. J Korean Pediatr Soc 2002;45: 1234-40
33 Saldanha J, Gerlich W, Lelie N, Dawson P, Heermann K, Heath A, et al. An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sang 2001;80:63-71   DOI   ScienceOn